Indian Pharma — Head-to-Head
Metric guide →Revenue
Total consolidated revenue in crore rupees. Reflects overall business scale and growth trajectory.
- Sun Pharma
- Cipla
- Divi's Labs
- Aurobindo
- Lupin
- Natco Pharma
EBITDA Margin
Operating profit as a percentage of revenue. Higher margins signal pricing power and competitive moats.
- Sun Pharma
- Cipla
- Divi's Labs
- Aurobindo
- Lupin
- Natco Pharma
R&D Spend (% Revenue)
Research and development spend as a percentage of revenue. Higher spend on specialty/novel drugs signals future growth investment.
- Sun Pharma
- Cipla
- Divi's Labs
- Aurobindo
- Lupin
- Natco Pharma
ROCE
Return on Capital Employed: operating profit as a percentage of total capital. The purest measure of business efficiency.
- Sun Pharma
- Cipla
- Divi's Labs
- Aurobindo
- Lupin
- Natco Pharma
ROE
Return on Equity: net profit as a percentage of shareholders' equity. Shows earnings generated on shareholder capital.
- Sun Pharma
- Cipla
- Divi's Labs
- Aurobindo
- Lupin
- Natco Pharma
Net Debt / EBITDA
Net debt as a multiple of annual operating profit. Below 1x is comfortable; above 2x warrants scrutiny.
- Sun Pharma
- Cipla
- Divi's Labs
- Aurobindo
- Lupin
- Natco Pharma
All data is for educational purposes only. Not investment advice. Read our disclaimer.